News
-
Neuronata-R ‘Ultimate’ coming out next year… CorestemChemon Completes Clinical Trial of Artificial Cerebrospinal Fluid.
2024.02.15
-
CorestemChemon Inc. "IDMC recommends to continue phase 3 clinical trial for ALS treatment Neuronata-R"
2024.02.07
-
CorestemChemon, 'Neuronata-R' Type C Meeting Complete... FDA Clinical Trial Phase 3 'Reasonable'
2023.12.19
-
Corestemchemon Phase 3 Patients Enrollment 100% Complete for Neuronata-R: The New Drug for ALS
2023.12.19
-
![[DI+Pharmaceutical Information] Corestemchemon, a Leading Pharmaceutical Company with the Innovative Drug for Stem Cells](/upload/press/202312/thumb/1702962598_m0175481_20231219140958.png)
[DI+Pharmaceutical Information] Corestemchemon, a Leading Pharmaceutical Company with the Innovative Drug for Stem Cells
2023.12.19
-
CorestemChemon Ground Breaking Advanced Biopharmaceutical Center... "Aims to Operate the Center in 2024"
2023.12.19
-
Corestemchemon Released the Data of Sales of NeuroNata-R in Conference of Amyotrophic Lateral Sclerosis in Asia-Pacific Region
2023.12.19
-
Corestemchemon Opened Its Branch in Washington, D.C. -- Realizing Entering the Global Market
2023.12.19
-
Corestemchemon "Neuronata-R, a Drug Treating Amyotrophic Lateral Sclerosis, Extended Living Period by 5.6 Years."
2023.12.19